1. Little, W. J. The classic: Hospital for the cure of deformities: course of lectures on the deformities of the human frame. 1843. Clin Orthop Relat Res 2012 470: 1252-6.
2. Sewell, M. D., Eastwood, D. M. & Wimalasundera, N. Managing common symptoms of cerebral palsy in children. BMJ 2014 349: g5474.
3. He, P., Chen, G., Wang, Z. et al. Children with motor impairment related to cerebral palsy: Prevalence, severity and concurrent impairments in China. J Paediatr Child Health 2017 53: 480-484.
4. Korzeniewski, S. J., Slaughter, J., Lenski, M. et al. The complex aetiology of cerebral palsy. Nat Rev Neurol 2018 14: 528-543.
5. Bhushan, V., Paneth, N. & Kiely, J. L. Impact of improved survival of very low birth weight infants on recent secular trends in the prevalence of cerebral palsy. Pediatrics 1993 91: 1094-100.
6. Sadowska, M., Sarecka-Hujar, B. & Kopyta, I. Cerebral Palsy: Current Opinions on Definition, Epidemiology, Risk Factors, Classification and Treatment Options. Neuropsychiatr Dis Treat 2020 16: 1505-1518.
7. Pakula, A. T., Van Naarden Braun, K. & Yeargin-Allsopp, M. Cerebral palsy: classification and epidemiology. Phys Med Rehabil Clin N Am 2009 20: 425-52.
8. Kancherla, V., Amendah, D. D., Grosse, S. D. et al. Medical expenditures attributable to cerebral palsy and intellectual disability among Medicaid-enrolled children. Res Dev Disabil 2012 33: 832-40.
9. Frank, R., Garfinkle, J., Oskoui, M. et al. Clinical profile of children with cerebral palsy born term compared with late- and post-term: a retrospective cohort study. BJOG 2017 124: 1738-1745.
10. Moster, D., Wilcox, A. J., Vollset, S. E. et al. Cerebral palsy among term and postterm births. JAMA 2010 304: 976-82.
11. Nelson, K. B. & Grether, J. K. Can magnesium sulfate reduce the risk of cerebral palsy in very low birthweight infants? Pediatrics 1995 95: 263-9.
12. Schendel, D. E., Berg, C. J., Yeargin-Allsopp, M. et al. Prenatal magnesium sulfate exposure and the risk for cerebral palsy or mental retardation among very low-birth-weight children aged 3 to 5 years. JAMA 1996 276: 1805-10.
13. Rao, R., Trivedi, S., Vesoulis, Z. et al. Safety and Short-Term Outcomes of Therapeutic Hypothermia in Preterm Neonates 34-35 Weeks Gestational Age with Hypoxic-Ischemic Encephalopathy. J Pediatr 2017 183: 37-42.
14. Novak, I., Morgan, C., Adde, L. et al. Early, Accurate Diagnosis and Early Intervention in Cerebral Palsy: Advances in Diagnosis and Treatment. JAMA Pediatr 2017 171: 897-907.
15. Jeck, W. R. & Sharpless, N. E. Detecting and characterizing circular RNAs. Nat Biotechnol 2014 32: 453-61.
16. Birney, E.Stamatoyannopoulos, J. A.Dutta, A. et al. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 2007 447: 799-816.
17. Salmena, L., Poliseno, L., Tay, Y. et al. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell 2011 146: 353-8.
18. Ashwal-Fluss, R., Meyer, M., Pamudurti, N. R. et al. circRNA biogenesis competes with pre-mRNA splicing. Mol Cell 2014 56: 55-66.
19. Pamudurti, N. R., Bartok, O., Jens, M. et al. Translation of CircRNAs. Mol Cell 2017 66: 9-21 e7.
20. Altesha, M. A., Ni, T., Khan, A. et al. Circular RNA in cardiovascular disease. J Cell Physiol 2019 234: 5588-5600.
21. Li, Y., Ge, Y. Z., Xu, L. et al. Circular RNA ITCH: A novel tumor suppressor in multiple cancers. Life Sci 2020 254: 117176.
22. Li, T. R., Jia, Y. J., Wang, Q. et al. Circular RNA: a new star in neurological diseases. Int J Neurosci 2017 127: 726-734.
23. Lei, B., Tian, Z., Fan, W. et al. Circular RNA: a novel biomarker and therapeutic target for human cancers. Int J Med Sci 2019 16: 292-301.
24. Li, Y., Zheng, Q., Bao, C. et al. Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis. Cell Res 2015 25: 981-4.
25. Hsiao, K. Y., Sun, H. S. & Tsai, S. J. Circular RNA - New member of noncoding RNA with novel functions. Exp Biol Med (Maywood) 2017 242: 1136-1141.
26. Ashwal, S., Russman, B. S., Blasco, P. A. et al. Practice parameter: diagnostic assessment of the child with cerebral palsy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2004 62: 851-63.
27. Ouyang, Q., Huang, Q., Jiang, Z. et al. Using plasma circRNA_002453 as a novel biomarker in the diagnosis of lupus nephritis. Mol Immunol 2018 101: 531-538.
28. Sun, H., Tang, W., Rong, D. et al. Hsa_circ_0000520, a potential new circular RNA biomarker, is involved in gastric carcinoma. Cancer Biomark 2018 21: 299-306.
29. Ji, W., Qiu, C., Wang, M. et al. Hsa_circ_0001649: A circular RNA and potential novel biomarker for colorectal cancer. Biochem Biophys Res Commun 2018 497: 122-126.
30. Salzman, J., Gawad, C., Wang, P. L. et al. Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types. PLoS One 2012 7: e30733.
31. Salzman, J., Chen, R. E., Olsen, M. N. et al. Cell-type specific features of circular RNA expression. PLoS Genet 2013 9: e1003777.
32. Salzman, J. Circular RNA Expression: Its Potential Regulation and Function. Trends Genet 2016 32: 309-316.
33. Jeck, W. R., Sorrentino, J. A., Wang, K. et al. Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA 2013 19: 141-57.
34. Dong, R., Ma, X. K., Chen, L. L. et al. Increased complexity of circRNA expression during species evolution. RNA Biol 2017 14: 1064-1074.
35. Tomita, H., Cornejo, F., Aranda-Pino, B. et al. The Protein Tyrosine Phosphatase Receptor Delta Regulates Developmental Neurogenesis. Cell Rep 2020 30: 215-228 e5.
36. Uhl, G. R. & Martinez, M. J. PTPRD: neurobiology, genetics, and initial pharmacology of a pleiotropic contributor to brain phenotypes. Ann N Y Acad Sci 2019 1451: 112-129.
37. Ansari, A., Maffioletti, E., Milanesi, E. et al. miR-146a and miR-181a are involved in the progression of mild cognitive impairment to Alzheimer's disease. Neurobiol Aging 2019 82: 102-109.
38. Zhang, Y., Shan, Z., Zhao, Y. et al. Sevoflurane prevents miR-181a-induced cerebral ischemia/reperfusion injury. Chem Biol Interact 2019 308: 332-338.
39. Ren, L., Zhu, R. & Li, X. Silencing miR-181a produces neuroprotection against hippocampus neuron cell apoptosis post-status epilepticus in a rat model and in children with temporal lobe epilepsy. Genet Mol Res 2016 15:
40. Moon, J. M., Xu, L. & Giffard, R. G. Inhibition of microRNA-181 reduces forebrain ischemia-induced neuronal loss. J Cereb Blood Flow Metab 2013 33: 1976-82.
41. Hegarty, S. V., Sullivan, A. M. & O'Keeffe, G. W. Inhibition of miR-181a promotes midbrain neuronal growth through a Smad1/5-dependent mechanism: implications for Parkinson's disease. Neuronal Signal 2018 2: NS20170181.
42. Stappert, L., Borghese, L., Roese-Koerner, B. et al. MicroRNA-based promotion of human neuronal differentiation and subtype specification. PLoS One 2013 8: e59011.
43. Hamada, N., Fujita, Y., Kojima, T. et al. MicroRNA expression profiling of NGF-treated PC12 cells revealed a critical role for miR-221 in neuronal differentiation. Neurochem Int 2012 60: 743-50.